Beam Therapeutics Inc. Common Stock
BEAMBeam Therapeutics Inc. (BEAM) is a biotechnology company focused on developing precision genetic medicines using base editing technology. Founded to create targeted therapies for genetic diseases, Beam Therapeutics leverages its innovative editing platform to make precise, single-nucleotide modifications in DNA, aiming to treat serious medical conditions with fewer off-target effects.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| March 3, 2014 | $0.23 | 2014-02-04 | 2014-02-06 |
| December 2, 2013 | $0.23 | 2013-11-04 | 2013-11-06 |
| September 3, 2013 | $0.23 | 2013-08-12 | 2013-08-14 |
| June 3, 2013 | $0.23 | 2013-05-06 | 2013-05-08 |
| March 1, 2013 | $0.23 | 2013-02-04 | 2013-02-06 |
Dividends Summary
- Consistent Payer: Beam Therapeutics Inc. Common Stock has rewarded shareholders with 41 dividend payments over the past 10 years.
- Total Returned Value: Investors who held BEAM shares during this period received a total of $11.96 per share in dividend income.
- Latest Payout: The most recent dividend of $0.23/share was paid 4344 days ago, on March 3, 2014.
- Yield & Schedule: BEAM currently pays dividends quarterly with an annual yield of 2.64%.
- Dividend Growth: Since 2004, the dividend payout has decreased by 25.0%, from $0.30 to $0.23.
Company News
Beam Therapeutics presented promising clinical trial results for risto-cel, a base editing cell therapy for sickle cell disease, showing high hemoglobin F induction, reduced hemoglobin S, and durable anemia resolution in 31 patients.
Several healthcare and AI-driven companies are demonstrating significant potential in transforming medical technologies, offering innovative therapies and solutions across various medical domains like gene editing, telehealth, and precision medicine.
Editas Medicine is a promising clinical-stage biotech company at the forefront of the gene-editing revolution with its unique in vivo CRISPR approach. However, the company faces significant technical challenges, a long road to commercialization, and weak fundamentals, making it a speculative investment.
Beam Therapeutics announced that the FDA has granted orphan drug designation to BEAM-302, a potential treatment for alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder affecting the lungs and liver. The designation provides benefits to support the development and evaluation of BEAM-302, which has shown promising initial safety and effi...
Beam Therapeutics, a gene-editing company, reported Q1 earnings that missed analyst expectations, leading to a 19% drop in its stock price. The company's cash runway extends into 2028, which could give it time to develop its pipeline programs.
